Complement receptor type 1 (CRI, CD35) is a membrane glycoprotein that is present on erythrocytes, leukocytes, glomerular podocytes, and splenic follicular dendritic cells, and mediates the binding by these cells of particles and immune complexes that have activated complement (1, 2) . This function of CRl is dependent on its capacity to bind reversibly the C3b and C4b fragments of C3 and C4 that are covalently attached to activators of complement . CRl also can inhibit complement activation by impairing the formation and function ofthe alternative and classical pathway C3/C5 convertases, and by serving as a cofactor for the cleavage by factor I of C3b to iC3b, C3c and C3d,g, and of C4b to C4c and C4d.
protein (C4bp), decay accelerating factor, complement receptor type 2, factor B, Clr, Cls, C2, and membrane cofactor protein (1, 5) . The presence of the SCR in the noncomplement proteins, the IL-2-R, factor XIIIb, and R-2-glycoprotein I, indicates that the SCR, although capable of forming a C3/C4-binding site, does not necessarily have this activity.
The present study is an analysis of the SCRs of CRI necessary to form the C3b/C4b-binding sites of CRl . The sequence of the NH2-terminal LHR, LHR-A, has been deduced from cDNA clones encoding this region of the receptor. A full-length cDNA clone containing all of the coding sequence of the F allotype of CRl has been constructed and expressed in L cells and in COS cells . The function ofthis recombinant CRI and of CRI-derived proteins encoded by a series of deletion mutants has been assessed and has permitted the mapping of functional domains .
Materials and Methods
Construction of a cDNA Library. A selectively primed cDNA library, XHH, was constructed from 3 ug of poly(A)' RNA purified from DMSO-induced HL-60 cells (6) (7) (8) as described with the modification that LK35 .1, a 35-mer oligonucleotide (5'-TGAAGTCATC ACAG-GATTTC ACTTCACATG TGGGG-3'), was used in place of oligo (dT),2-,s > and 40 gCi of a-[s 2 P]dCTP was added during second strand synthesis . One third of the cDNA was cloned in ?.gtll and 750,000 independent recombinants were obtained . The size-selected human tonsil library, XS2T, has been previously described (4, 9) (American Type Culture Collection accession No . 37546) .
Isolation of Clones, Probes, and DNA Sequence Analysis . The probes used for screening cDNA libraries study were CRI-1 (9) (American Type Culture Collection, accession No . 57331), CRI-2 (9), CRI-4 (10), and CRI-18, a 252-bp Sau 3AI fragment from the 0 .5-kb Eco RI fragment of cDNA clone XH3 .1 corresponding to nucleotides 101-352 in Fig . 1 . Under conditions of high stringency, CRl-18 hybridizes only to cDNA clones encoding either the NH2-terminal SCR of LHRA or the signal peptide. The inserts of the cDNA clones were sequenced by the dideoxynucleotide technique (11) after subcloning fragments into M13mp18 and M13mp19 (12) . Deletion mutants for sequencing were made by the exonuclease III method (13) . Deletion constructions for expression were sequenced directly from the double-stranded plasmid as described (14) . DNA sequences were aligned and analyzed with the UWGCG package (15) or the MicroGenie software (Beckman Instruments, Inc ., Fullerton, CA) .
Strains and Plasmids. Escherichia coli MC1061/P3 and the CDM8 expression vector (16) , were gifts from Dr. Brian Seed (Massachusetts General Hospital, Boston, MA). The expression vector, pMTneo.l, was a gift from Dr. Keith Peden (The Johns Hopkins University School of Medicine, Baltimore, MD) . E. coli GM48 and GM271, dam and dcm -, respectively, were gifts from Dr. Elizabeth Rayleigh (New England Biolabs, Beverly, MA) and E. coli DKl, a recA derivative of MC1061, was a gift from Dr. David Kurnit (University ofMichigan Medical School, Ann Arbor, MI) . Strains DKI/P3 and GM271/P3 were prepared by transforming the indicated parental strain with plasmid DNA isolated from MC1061/P3 and selecting for kanamycin resistance. Strain DH5a (Bethesda Research Laboratories, Bethesda, MD), pBluescript KS' (Stratagene, Madison, WI), and pGEM3b (Promega Biotec, LaJolla, CA) were obtained as indicated .
Construction ofpBSABCD andpiABCD. Restriction fragments derived from the cDNA clones, XT109 .1, XH10.3, XH7 .1, XT8 .3 (9), XT6.1 (4, 10), XT50.1 (4), and XT8.2 (4) were ligated and inserted into pBluescriptKS' to form pBSABCD (Fig . 1) . The 6 .9-kb Xho I/Not I fragment containing the entire CRl cDNA coding sequence was ligated to the 4.4-kb Xho I/Not I fragment of CDM8 (Fig . 4) , the ligation mixture used to transform DKl/P3, and the clone, piABCD, containing the CRI cDNA insert was selected.
Construction of CRI Deletion Mutants. The construction of the deletion mutants utilizes the four Bsm I sites in homologous positions near the sequence encoding the NH2 terminus of each of the four LHRs and the absence of Bsm I sites elsewhere . 10 wg of pBSABCD DNA was partially digested with 50 U of Bsm I for 45 min, and the restriction fragments of 8.55, 7.20, and 5.85 kb that corresponded to linear segments of the parent plasmid lacking sequence encoding one, two, or three LHRs, respectively, were purified, self ligated, and used to transform competent DH5a.
The 8.55-kb fragment was generated from pBSABCD by releasing any one of three 1.35-kb Bsm I fragments corresponding to the coding sequence for 92% of LHR A, -B, or -C. Thus, three distinct plasmids distinguishable by restriction mapping with Sma I were generated after ligation : pBSBCD, pBSBCD, and pBSBCD, in which the capital letters following pBS represent the LHRs present. The 5 .6-kb insert of each of these constructs was released by digestion with Xho I/Not I and ligated to the expression vector, CDM8, to form piBCD, piABD, and piACD. The 7.20-kb fragment from the partial digestion of pBSABCD resulted from Bsm I digestion at three adjacent sites or at two sites separated by a single uncut site. The two possible products obtained after ligation and transformation, pBSAD, and pBSCD, were distinguished by digestion with Xho I/Pst I . The 4.2-kb insert was released from each by digestion with Xho I/Not I and subcloned into CDM8 to yield piAD and piCD. The 5.85-kb fragment from the Bsm I digestion ofpBSABCD represented a product ofcomplete digestion and was self ligated to form pBSD. The 2.9-kb insert of pBSD was released with Xho I/Not I and ligated into CDM8 to yield piD.
The plasmid, pBSBD, was prepared by Bsm I partial digestion of pBSBCD. The linear 7.2-kb fragment corresponding to cleavage of two adjacent Bsm I sites was self-ligated and used to transform DH5a . The 4.2-kb insert containing 1.2 and 6.0 kb Sma I fragments was released with Xho I/Not I and transferred to CDM8 to yield piBD.
The plasmid piABCD was digested to completion with Bst EII, and a doublet of 1 .35 kb and a single fragment of 8.6 kb were ligated and the mixture was used to transform DKI/P3 . Colonies were identified by hybridization with the CRI cDNA probe, CRI-4, and the DNA of positive clones was digested with Sma I. The plasmid, piE-2, was identified as containing a weakly CRI-4' clone having a single 8.6-kb Sma I fragment .
The plasmid, piA/D, was prepared by digesting piABCD to completion with Pst I and partially with Apa I. The 3' overhangs were removed with the Klenow fragment of E. coli DNA polymerase I. A 7 .5-kb fragment was ligated and used to transform DKI/P3 .
Transfection of Recombinant CRI Plasmids. Each 30-50% confluent 10-cm dish of COS cells or L cells was transfected with 8 Rg of DNA and 1.6 mg of DEAE-dextran in the presence of 100 uM chloroquine diphosphate (8) . The transfected cells were shocked with 10% DMSO (17) and cultured for 2-3 d in DMEM supplemented with 10% FCS, 2 mM glutamine, 50 U/ml penicillin, 50 gg/ml streptomycin, and 1 mM sodium pyruvate.
RIA, Immunofuorescence, and Immunoprecipitation of Recombinant CRI . Replicate samples of 3 x 105 transfected cells in 0.1 ml PBS containing 1% BSA and 0.02% sodium azide were incubated at 0°C for 60 min with 3 gg/ml YZl IgGI anti-CRI (18) or with 90 ug/ml rabbit IgG anti-CRI . The cells were washed and resuspended in 0.1 ml of buffer containing 1-2 gCi/ml of 125I-F(ab')2 goat anti-mouse IgG or 125 1-protein A. After 1-2 h at 0°C, the cells were washed and assayed for 125 1.
For immunofluorescent detection of CRI, transfected cells were sequentially incubated with YZl anti-CR1 and affinity-purified FITC-labeled sheep F(ab')2 anti-mouse IgG (Cappel Laboratories, Cochranville, PA) .
CRI was immunoprecipitated from detergent lysates of 125 1-surface-labeled (19) cells with Sepharose YZl or with rabbit IgG anti-CRI/protein A-Sepharose (18) . Immunoadsorbed proteins were assessed by SDS-PAGE (20) and autoradiography.
Assay of Recombinant CRI Function . Sheep erythrocytes sensitized with rabbit antibody (EA) and limited amounts of C4b (EAC4b [lim]) and 12,000 125 1-Cab/cell (EAC4b [lim], 3b) were prepared by sequential treatment of EAC4b (lim) (Diamedix, Miami, FL) with Cl, C2, and 1251-C3 followed by incubation for 60 min at 37°C in gelatin veronal-buffered saline containing 40 mM EDTA. Alternatively, methylamine-treated C3 (C3 [ma] ) and (C4 [ma]) were covalently attached to sheep erythrocytes treated with 3-(2-pyridyldithio) propionic acid N-hydroxysuccinimide ester (Sigma Chemical Co., St. Louis, MO) (21) . EAC4b were prepared with purified C4 (22) .
The C3-and C4-binding functions of recombinant CRI were assayed by rosette formation. Transfected cells, 1-4 x 106/ml, were incubated with C3-or C4-bearing erythrocytes, 2-6 x 106 /ml, in 0 .02 ml for 60 min at 20°C. The percentage of transfected cells forming rosettes was evaluated microscopically with a transfected cell scored as a rosette if there were at least five adherent erythrocytes .
The factor 1-cofactor function of recombinant CRI was assessed by incubating transfected COS cells with 0 .5 gg' 25 I-C3(ma) and 0 .2 ltg factor I (23) in 0 .04 ml for 60 min at 37°C followed by SDS-PAGE and autoradiography. Alternatively, detergent lysates of 106 COS cells were immunoprecipitated sequentially with Sepharose-UPC10 anti-levan and Sepharose YZl . The washed beads were incubated for 60 min at 37°C with '211-C3(ma) and factor I in 0 .05 ml PBS-0 .5% NP-40 . DNA sequence analysis of XH3.1 revealed that the open reading frame continued to the 5' end of the cDNA, indicating that the clone did not extend to the translational start site . Therefore, the cDNA libraries, XHH and XS2T (4, 9), were rescreened with the probe CRl-18 to identify one clone from each 1H10 .3 and XT109.1, respectively. The Eco RI fragments of these clones that hybridized with CR1-18 were sequenced as were the inserts from the clones XH3 .1 and XH7.1 . The composite sequence is presented such that the nucleotide following 1531 in Fig. 2 is nucleotide 1 in Fig. 2 of the previously published sequence (4). The overlapping sequences of the cDNA clones from the HL-60 and tonsillar libraries are identical.
Immediately upstream of LHR-A, clones XH10 .3 and XT109.1 contain identical putative hydrophobic leader sequences (24) encoding 41 amino acids, including an ATG matching the consensus NNA/GNNATGG proposed for eukaryotic translation initiation sites ( Fig. 3) (25) . A second ATG, located six codons upstream of the chosen ATG and just downstream of an in-frame stop codon, is a poor match 
The deduced amino acid sequence of the 5' cDNA clones encoding the seven SCRs of LHRA, and alignment of this sequence with the corresponding SCRs of LHRB, -C, and -D. The four cysteines that are conserved in each SCR are underlined . A residue is shown for LHR-B, -C, and -D only where it is different from that in LHRA. These sequence data have been submitted to the EMBL/GenBank under the accession number Y00816 .
for this consensus sequence . The first three amino acids of this leader sequence for CRI, MGA, are the same as those reported for CR2 (1) . The sequences of these two clones diverge upstream of the ATG, and that from clone XH10.3 is believed to represent a portion of an intervening sequence (data not shown) as has been described earlier for other CR1 cDNA clones (4).
The signal peptidase cleavage is predicted (24) to occur between glycine-46 and glutamine-47, suggesting that the blocked NH2 terminus of CRI (26, 27) may be due to the presence of a pyrrolidone amide. The first two SCRs of the NH2-terminal LHR-A contained in these clones are only 61 % identical to the corresponding region of LHRB, whereas SCRs 3-7 of LHRA are 99% identical to the corresponding SCRs of LHRB (Fig. 3) . Comparison of LHRA with LHR-C reveals that only the third and fourth SCRs ofeach are highly homologous (99% identical) . LHR-A and -D have only 68°Io overall identity, with maximal identity of 81% between the sixth SCR of each LHR. Thus, completion of the 5' cDNA sequence of CRI indicates that the F allotype is composed of 2,039 amino acids, including a 41-amino acid signal peptide, four LHRs ofseven SCRs each, two additional COOH-terminal SCRs, a 25-residue transmembrane region and a 43-amino acid cytoplasmic domain. There are 25 potential N-linked glycosylation sites.
Expression ofRecombinant CRI Protein . Restriction fragments of eight cDNA clones were ligated to form the plasmid, pBSABCD, having the entire coding sequence of the F allotype of human CRI (Fig . 1) . The 6.9-kb Xho I-Not I fragment of pBSABCD containing this sequence was subcloned into the eukaryotic expression vectors, CDM8, to form piABCD and pMTneo.1 to form pMTABCD (Fig. 4) . Expression of the insert is driven from a cytomegalovirus promoter in piABCD and from the mouse metallothionein promoter in pMTABCD; both plasmids contain an SV40 polyadenylation signal . The "ABCD" notation refers to the LHRs that are present in the expression constructs. Murine L cells were cotransfected by the DEAE-dextran method (8, 17) in duplicate with 0, 2, or 4 ug of either piABCD or pMTABCD and 2 ug of pXGH5, a reporter plasmid that directs the expression of growth hormone (28) . The cells were harvested after 2 d and assayed for expression ofCR1 by binding ofYZ1 monoclonal anti-CR1 . There was a dose-response relationship between recombinant plasmid DNA and the expression of CR1 antigen (Table I ). The plasmid, piABCD, directed the expression ofnearly threefold more CR1 antigen than did pMTABCD. The growth hormone concentration in the culture medium varied by less than twofold with the exception ofplate 5 . Additional experiments revealed that piABCD directed the tran- (29) .
The Mr of the recombinant CRI was determined by surface iodination of COS cells transfected with piABCD, immunoprecipitation of cell lysates with Sepharose-YZI, SM" PAGE, and autoradiography. The recombinant CRI had an Mr of 190,000 unreduced, which was equivalent to that of the F allotype and less than that of the S allotype of erythrocyte CRI (Fig. 6) .
The Cab-binding and C4b-binding function of recombinant CRI was assayed by the formation of rosettes between the transfected COS cells and EAC4b or EAC4b(lim),3b. In 31 separate transfections, 5-50% of COS cells transfected with the plasmid, piABCD, bound five or more EAC4b or EAC4b(lim),3b (Fig . 7) . The COS cells expressing CRI did not form rosettes with EAC4b(lim),3bi, although this intermediate did form rosettes with Raji B lymphoblastoid cells expressing CR2 (data not shown).
The factor 1-cofactor activity of recombinant CRI immunoadsorbed from detergent lysates of transfected COS cells with Sepharose-YZI was evaluated by incubation with 0.5 pg of 125 1-C3(ma) and 200 ng of factor I . Factor I cleaved the a chain of C3(ma) into fragments of 76,000 and 46,000 Mr only in the presence of immunoimmobilized recombinant CRl or factor H (Fig. 8) . The regions corresponding to bands from the autoradiogram were excised from the gel and assayed for 1251 to determine the amount of the a chain cleaved. In the presence of factor H, 91% of the a chain was cleaved, while in the presence of increasing amounts of recombinant CRl, 267o, 41%, and 5570, respectively, was cleaved.
Identification andLocalization ofMultiple C3b/C4b-bindingSites in CR1. Deletion mutagenesis of recombinant CR1 was performed to determine whether multiple distinct C4b/C3b-binding sites are present in the receptor. The clones piBCD, piAD, piBD, piCD, and piD were prepared from partial digests of the full coding sequence of CRl cDNA with Bsm I, which restricted the DNA at single sites near the sequence encoding the second cysteine of the first SCR of each LHR (Fig. 9) . After ligation ofthe various restriction fragments, deletion mutants lacking one, two, or three LHRs were generated.
The clone piA/D was prepared by digesting the CR1 cDNA with Pst I and Apa I, which restricted the DNA at a site between the codons for cysteine-3 and -4 of the fifth SCR of LHRA and cysteine-3 and -4 of the fourth SCR ofLHRD, respectively (Fig. 9) . Ligation of the appropriate fragments formed a hybrid construct containing the NH2-terminal four and three quarters SCRs of LHRA and the COOHterminal three and one quarter SCRs of LHRD.
The clone piE-2 was prepared by digesting the CRl cDNA with Bst EII, which restricted the DNA at a site between the codons for cysteine-1 and -2 of the third SCR of LHR-A, -B, and -C, respectively (Fig. 9) . Ligating the 5' LHRA-encoding fragment to the fragment encoding the 3' end of LHRC and the rest of the 3' sequence created a construct in which SCR-1 and -2 of LHR-A were substituted for the corresponding SCRs of LHRC, with deletion of the rest of LHRA and all of LHRB. COS cells transiently expressing the piABCD, piBCD, piCD, and piD constructs, respectively, were surface labeled with 1251 and immunoprecipitated with anti-CRI . On SDS-PAGE after reduction, the product of the piABCD construct comigrated with the F allotype ofCR1, while the deletion mutants demonstrated stepwise decrements of "45,000 Mr, indicative of the deletion of one, two, and three LHRs, respectively (Fig. 10) . 7) and COS cells transfected with CDM8 vector alone (lanes 2 and 8), piABCD (lanes 3 and 9), piBCD (lanes 4 and 10), piCD (lanes 5 and 11), and piD (lanes 6 and 12), respectively, were immunoprecipitated with Sepharose-UPC10 anti-levan (lanes 1-6), SepharoseYZ-1 anti-CR1 (lanes 7-11), and rabbit anti-CR1 and protein A-Sepharose (lane 12), respectively. The eluates were subjected to SDS-PAGE under reducing conditions and autoradiography.
In each of three separate experiments, the proportion of COS cells expressing the full-length piABCD construct that formed rosettes with the EC3(ma) was similar to the fraction having detectable recombinant receptor, as assessed by immunofluorescence using either YZ1 monoclonal anti-CR1 or rabbit anti-CRI (Table II ). In contrast, cells expressing piD did not form rosettes, indicating that a C3-binding site(s) must reside in or require the presence of LHRA, -B, or -C . A site was shown to be present in both LHRB and -C by demonstrating that cells expressing either the piBD or piCD constructs formed rosettes with EC3(ma). Cells expressing piAD, piA/D, or piE-2 did not have equivalent C3-binding function . As the piE-2 construct differs from piCD only in having SCR-1 and -2 of LHRA instead of the first two SCRs of LHR-C, the function of the C3-binding site in LHRC must require these NH2-terminal SCRs .
The proportion of COS cells expressing the full-length piABCD recombinant that formed rosettes with EC4(ma) was less than the fraction rosetting with EC3(ma), perhaps reflecting fewer C4(ma) per erythrocyte (Table II) or fewer C4-binding sites per receptor. Deletion mutants having all or part of LHRA, the piAD, piA/D, and piE-2 constructs, bound EC4(ma) better than did the deletion mutants, piBD and piCD; piD lacked this function . Thus, the C4-binding site ofCRl resides primarily in LHR-A, although secondary sites may be present in LHRB and -C . The improved rosetting capability of the piE-2 construct relative to that of piCD suggests that SCR-1 and -2 of LHRA are involved in the C4-binding site.
RIA of the binding of YZI monoclonal anti-CRI indicated significant uptake by COS cells expressing the piABCD, piAD, piBD, and piCD constructs (Table III) . Cells transfected with piD or piA/D, which is composed of the five NH2-terminal SCRs of LHRA and the three COOH-terminal SCRs of LHR-D, did not bind YZl anti-CR1, although the products of these constructs bound polyclonal anti-CRI (Table   TABLE II Formation of Rosettes between COS Cell Transfectants Expressing Recombinant Forms of CRI and Sheep Erythrocytes Bearing C3(ma) or C4(ma)
The numbers of C3 (ma)/E were 60,000, 350,000, and 900,000, respectively, in the three experiments using this intermediate . The number of C4 (ma)/E were 160,000 and 140,000, respectively, in the two experiments using this intermediate . III). Thus, the YZl epitope is repeated in LHRA, -B, and -C, is not present in the NH2-terminal SCRs of LHRA, and is not present or is inaccessible in LHRD. Factor I Cofactor Function of the CRI Deletion Mutantsfor Cleavage of C3. COS cells transfected with piABCD, piAD, piBD, piCD, and piD, respectively, were incubated with 1251-C3(ma) and factor I to evaluate factor I-cofactor activity. In contrast to the experiment depicted in Fig. 8 , the recombinant CRI was assayed on intact COS cells because the product of the piD construct cannot be immunoadsorbed by SepharoseYZI (Table 111) . Although the COS cells transfected with the CDM8 vector alone contained some endogenous factor I-cofactor activity, an increase in this function was evident with COS cells transfected with piABCD, piBD, and piCD (Fig. 11) . No enhanced cleavage of 125 1-C3(ma) was seen with COS cells transfected with piAD or piD. Thus, among these constructs, only the deletion mutants, piBD and piCD, which conferred on COS cells a capacity for binding C3, also had factor I-cofactor activity for cleavage of C3 .
Discussion
The primary structure of the NH2 terminus and the signal peptide of the F allotype of CRI has been deduced by the isolation and sequencing of 5' cDNA clones . The highly repetitive nature of the CRI sequence made critical the development of an appropriate strategy for the preparation and identification of cDNA clones encoding this region ofthe receptor. A cDNA library was prepared using as a primer a 35-mer oligonucleotide known to hybridize under the conditions of reverse transcription to LHRB, -C, and -D ; the possibility was considered that this primer might hybridize also to LHR-A that had been predicted to be highly homologous to LHR-B (4). Appropriate cDNA clones would be identified by the use of another oligonucleotide, KS23 .1, which would hybridize only to LHRB under stringent conditions, thereby increasing the probability of finding 5' cDNA clones . Two clones were found that encompassed almost all of the residual sequence of CRI, and a Sau 3AI fragment of one of these, CRI-18, had sequence sufficiently unique to permit its use in the identification of the remaining 5' clones (Figs. 1-3) .
Amino acid sequencing studies ofCRI purified from erythrocyte membranes had revealed that the NH2 terminus was blocked (26, 27) . Therefore, unambiguous demonstration that the full-length sequence of CRl had been completed required Cleavage of 125 1-C3(ma) by factor I in the presence of COS cells expressing fulllength and deletion mutants of CRI. Replicate samples of 125 1-C3(ma) were incubated with COS cells transfected with the CDM8 vector alone (lanes I and 7), piABCD (lanes 2 and 8), piAD (lanes 3 and 9), piBD (lanes 4 and 10), piCD (lanes 5 and 11), and piD (lanes 6 and 12), respectively, in the absence (lanes 1-6) or presence of factor I (lanes 7-12). Samples of 125 1-C3(ma) also were incubated with factor H and factor I (lane 13) and with factor I alone (lane 14), respectively. After reduction, the 125 1-C3(ma) was analyzed by SDS-PAGE and autoradiography. expression of recombinant receptor and comparison with wild-type CR1 . Restriction fragments of eight cDNA clones were ligated and the putative full-length construct was inserted into two expression vectors (Fig . 4) to direct the synthesis of the recombinant receptor detectable by immunofluorescence on COS cells (Fig. 5) . The recombinant CR1 was indistinguishable from the F allotype of erythrocytes by SDS-PAGE (Fig . 6) , it mediated the binding of sheep erythrocytes bearing either C4b or C3b, reproducing the ligand specificity of CRI (Fig . 7) , and it exhibited factor 1-cofactor activity for cleavage of the a polypeptide of C3(ma) (Fig . 8) . Thus, all of the coding sequence of the F allotype CRl had been cloned and, after cleavage of the signal peptide of 41 amino acids, the mature receptor contained 1,998 amino acids, including an extracellular domain of 1,930 residues that forms 30 SCRs, 28 of which are organized into LHR-A, -B, -C, and -D (Fig. 3) , a single membranespanning domain of 25 amino acids and a relatively short cytoplasmic domain of 43 amino acids (4) .
Among the C3/C4-binding proteins that contain multiple SCRs, CR1 is unique in having groups of SCRs organized into LHRs . Comparison of the four LHRs of CRI reveals that each is a composite of four types of SCRs: types a, b, c, and d (Fig . 12) . For example, the sequences of SCR-1 and -2 of LHR-A are only 62%, 62%, and 57% identical to the first two SCRs of LHR-B, -C, and -D, respectively. However, SCR-3 through SCR-7 differ from the corresponding SCRs of LHR-B at only a single position, and SCR-3 and -4 differ from those of LHR-C at only three positions (Fig . 3) . Thus, some of the type "a" SCRs of LHR-A are also present in rnI,
FIGURE 12 . Schematic model depicting the types of SCRs composing each LHR of CR1, and the predicted sites determining the specificities of the receptor for C3b and C4b. The secondary binding specificities of these are indicated by the parentheses.
LHRB and -C . The first two SCRs of LHR-B, which differ from those of LHRA, are 99% identical to the corresponding SCRs of LHRC, so that LHRB and -C share the type "b" SCR at these positions. The fifth, sixth, and seventh SCRs of LHRC are only 77% identical to the type "a" SCRs in LHRA and -B at these positions, and are considered as type "c" SCRs. The first through fourth SCRs of LHR-D are relatively unique and are type "d", while the fifth through seventh SCRs are -93 1 7o identical to the "c" type found in LHR-C. This mosaic composition of the LHRs, which may have arisen through gene conversion or homologous recombination with unequal crossover, provided an experimental approach for determining those SCRs involved in the C4 and C3 specificity of CRl. The conserved Bsm I site found midway through the coding sequence of the first SCR of each LHR permitted the construction of a series of deletion mutants that corresponded closely to the boundaries of the LHRs, and maintained the open reading frame and the appropriate positions ofthe four cysteines necessary for the presumed disulfide bond formation (Fig. 9) . Comparison of the C3(ma)-and C4(ma)-binding functions of these deletion mutants would distinguish not only the LHRs having these specificities, but also those SCRs critical for determining the ligand specificity. Thus, the capacity of piAD, piA/D, and piE-2 forms of the receptor, but not the piD form, to mediate rosette formation between the transfected COS cells and EC4(ma) indicated that the NH2-terminal two SCRs of LHRA contained a site for interaction with this complement protein (Table II) . This site was only relatively specific for C4(ma) because transfectants expressing piAD and piA/D also were capable of binding EC3(ma) ( Table II) . The C3(ma)-binding function of the receptors encoded by the piBD and piCD constructs, demonstrated by rosette assay and factor I-cofactor function for cleavage of C3(ma) (Table II; Fig. 11 ), indicated the presence of sites specific for C3(ma) in the first two SCRs ofthese LHRs. These sites also were capable of interacting with C4(ma) ( Table II) . The finding of preferential, but overlapping, C4-and C3-binding activities in LHRA, -B, and -C is not unprecedented, as both factor H and C4b-binding protein have been found to have secondary specificities for C4b and C3b, respectively (30, 31) , a finding that perhaps reflects shared structural features in C3 and C4 . Alternatively, the capacity of the COS cells expressing the piBD and piCD constructs to bind EC4(ma) may have been caused by the transfer of nucleotides encoding the NH2-terminal 36 amino acids from SCR-1 of LHRA to LHRB, and -C through the ligation of the Bsm I fragments. However, these 36 amino acids alone did not confer on the piD product C4-rosetting function . We cannot exclude a secondary function of LHRD in these reactions because this LHR was present in all the constructs assayed for function . The finding of three distinct ligand recognition sites in CR1, two for C3b and one for C4b (Fig. 12) , indicates that each receptor molecule may be capable of effectively binding complexes bearing multiple C4b and C3b molecules despite having a relatively low affinity for monovalent ligands (32) . This finding also provides an explanation for the inability of soluble C4b to inhibit formation of rosettes between erythrocytes bearing C3b and a human B lymphoblastoid cell line (33) . The recent description of covalent complexes between C4b and C3b (34) , and perhaps between C3b molecules, suggests that possible ligands for which CRI would be especially adapted may be the molecular complexes C4b/C3b and C3b/C3b, which are generated during activation of the classical and alternative pathways, respectively. The presence of distinct binding sites in three of the four LHRs also suggests that the CRI structural allotypes differing by their number of LHRs may have significant functional differences caused by variations in the number of ligand-binding sites. Although in vitro studies have not reported differing binding activities of the F, S, and F (A-C, respectively) allotypes, the smaller F allotype, presumably having only three LHRs, has been reported possibly to be associated with systemic lupus erythematosus (3), perhaps reflecting an impaired capability of this allotype to participate in the clearance of immune complexes.
The demonstration that the epitope recognized by YZ1 monoclonal anti-CR1 was present in LHR-A, -B, and -C indicates that prior estimates based on the binding of this antibody of the number of CR1 molecules expressed by various cell types may be excessive (35, 36) . Supporting this conclusion is an earlier study in which the concentration of CRI in a purified preparation of receptor estimated by an assay using YZl was 2.7-fold greater than that estimated by protein determination (26) . In addition, studies have reported variation in the number of erythrocyte epitopes recognized by different mAbs (37, 38) . However, the low number of CR1 sites on erythrocytes of patients with lupus cannot be accounted for by abnormal expression of epitopes as patients and normals have the same frequency of the F and S allotypes, and diminished numbers of receptors were also found when assayed by the binding of soluble C3b (39) .
Summary
Complementary DNA clones encoding the NH2-terminal region of human CR1 have been isolated and sequenced. The deduced complete amino acid sequence of the F allotype of human CRI contains 2,039 residues, including a 41-residue signal peptide, an extracellular domain of 1,930 residues, a 25-amino acid transmembrane domain, and a 43-amino acid cytoplasmic region . The extracellular domain is composed exclusively of 30 short consensus repeats (SCRs), characteristic of the family of C3/C4-binding proteins . The 28 NH2-terminal SCRs are organized as four long homologous repeats (LHRs) of seven SCRs each . The newly sequenced LHR, LHRA, is 61% identical to LHR-B in the NH2-terminal two SCRs and >99% identical in the COOH-terminal five SCRs . Eight cDNA clones were spliced to form a single construct, piABCD, that contained the entire CR1 coding sequence downstream of a cytomegalovirus promoter. COS cells transfected with piABCD transiently expressed recombinant CR1 that comigrated with the F allotype of erythrocyte CRI on SDS-PAGE and that mediated rosette formation with sheep erythrocytes bearing C4b and C3b. Recombinant CRI also had factor I-cofactor activity for cleavage of C3(ma) . Analyses of six deletion mutants expressed in COS cells indicated that the N112-terminal two SCRs of LHRA contained a site determining C4 specificity and the NH2-terminal two SCRs of LHR B and -C each had a site determining C3 specificity. The presence of these three distinct sites in CRl may enable the receptor to interact multivalently with C4b/C3b and Cab/C3b complexes generated during activation of the classical and alternative pathways .
